Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Huntington's Disease Clinical Trials Corner: June 2019.

Rodrigues FB, Ferreira JJ, Wild EJ.

J Huntingtons Dis. 2019 Jul 29. doi: 10.3233/JHD-199003. [Epub ahead of print]

PMID:
31381524
2.

Electronic search strategies fail to identify randomized controlled trials (RCTs) in neurosurgery.

Gorayeb RP, Forjaz MJ, Ferreira AG, Duarte GNS, Machado T, Ferreira JJ.

Clin Neurol Neurosurg. 2019 Sep;184:105446. doi: 10.1016/j.clineuro.2019.105446. Epub 2019 Jul 14. Review.

PMID:
31377675
3.

Nocebo response in Parkinson's disease: A systematic review and meta-analysis.

Leal Rato M, Duarte GS, Ferreira AN, Alves M, Mainoli B, Teodoro T, Mestre TA, Costa J, Ferreira JJ.

Parkinsonism Relat Disord. 2019 Apr 20. pii: S1353-8020(19)30210-X. doi: 10.1016/j.parkreldis.2019.04.015. [Epub ahead of print] Review.

PMID:
31103487
4.

Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria?

Fabbri M, Zibetti M, Ferrero G, Accornero A, Guimaraes I, Rizzone MG, Romagnolo A, Ferreira JJ, Lopiano L.

Parkinsonism Relat Disord. 2019 Apr 28. pii: S1353-8020(19)30213-5. doi: 10.1016/j.parkreldis.2019.04.018. [Epub ahead of print]

PMID:
31060986
5.

MDS evidence-based review of treatments for essential tremor.

Ferreira JJ, Mestre TA, Lyons KE, Benito-León J, Tan EK, Abbruzzese G, Hallett M, Haubenberger D, Elble R, Deuschl G; MDS Task Force on Tremor and the MDS Evidence Based Medicine Committee.

Mov Disord. 2019 Jul;34(7):950-958. doi: 10.1002/mds.27700. Epub 2019 May 2. Review.

PMID:
31046186
6.

Corrigendum to "Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis" [Arch. Gerontol. Geriatr. 81 (March-April) (2019) 209-214].

Caldeira D, Nunes-Ferreira A, Rodrigues R, Vicente E, Pinto FJ, Ferreira JJ.

Arch Gerontol Geriatr. 2019 Jul - Aug;83:338. doi: 10.1016/j.archger.2019.04.008. Epub 2019 Apr 26. No abstract available.

PMID:
31036372
7.

A critique of the second consensus criteria for multiple system atrophy.

Stankovic I, Quinn N, Vignatelli L, Antonini A, Berg D, Coon E, Cortelli P, Fanciulli A, Ferreira JJ, Freeman R, Halliday G, Höglinger GU, Iodice V, Kaufmann H, Klockgether T, Kostic V, Krismer F, Lang A, Levin J, Low P, Mathias C, Meissner WG, Kaufmann LN, Palma JA, Panicker JN, Pellecchia MT, Sakakibara R, Schmahmann J, Scholz SW, Singer W, Stamelou M, Tolosa E, Tsuji S, Seppi K, Poewe W, Wenning GK; Movement Disorder Society Multiple System Atrophy Study Group.

Mov Disord. 2019 Jul;34(7):975-984. doi: 10.1002/mds.27701. Epub 2019 Apr 29. No abstract available.

PMID:
31034671
8.

Proper or Improper Use of the Crossover Design in Clinical Trials in Chronic Sciatica?

Leal Rato M, Duarte GS, Ferreira JJ.

JAMA Neurol. 2019 Jun 1;76(6):731. doi: 10.1001/jamaneurol.2019.0870. No abstract available.

PMID:
31034000
9.

Dysphagia predicts poor outcome in late-stage Parkinson's disease.

Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Godinho C, Cardoso R, Guimaraes I, Antonini A, Zibetti M, Lopiano L, Ferreira JJ.

Parkinsonism Relat Disord. 2019 Mar 2. pii: S1353-8020(19)30089-6. doi: 10.1016/j.parkreldis.2019.02.043. [Epub ahead of print]

PMID:
30902528
10.

Morphine in acute coronary syndrome: systematic review and meta-analysis.

Duarte GS, Nunes-Ferreira A, Rodrigues FB, Pinto FJ, Ferreira JJ, Costa J, Caldeira D.

BMJ Open. 2019 Mar 15;9(3):e025232. doi: 10.1136/bmjopen-2018-025232.

11.

Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.

Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ.

PLoS One. 2019 Feb 20;14(2):e0211228. doi: 10.1371/journal.pone.0211228. eCollection 2019.

12.

Integrating genetic and physical positions of the anthracnose resistance genes described in bean chromosomes Pv01 and Pv04.

Murube E, Campa A, Ferreira JJ.

PLoS One. 2019 Feb 14;14(2):e0212298. doi: 10.1371/journal.pone.0212298. eCollection 2019.

13.

Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Eur J Neurol. 2019 Jul;26(7):953-960. doi: 10.1111/ene.13914. Epub 2019 Mar 25.

14.

Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis.

Caldeira D, Nunes-Ferreira A, Rodrigues R, Vicente E, Pinto FJ, Ferreira JJ.

Arch Gerontol Geriatr. 2019 Mar - Apr;81:209-214. doi: 10.1016/j.archger.2018.12.013. Epub 2018 Dec 27. Erratum in: Arch Gerontol Geriatr. 2019 Jul - Aug;83:338.

PMID:
30612074
15.

Optogenetics: the new molecular approach to control functions of neural cells in epilepsy, depression and tumors of the central nervous system.

Camporeze B, Manica BA, Bonafé GA, Ferreira JJC, Diniz AL, de Oliveira CTP, Mathias Junior LR, de Aguiar PHP, Ortega MM.

Am J Cancer Res. 2018 Oct 1;8(10):1900-1918. eCollection 2018. Review.

16.

Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.

Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the Movement Disorder Society Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 Jan 3;5(2):111-117. doi: 10.1002/mdc3.12571. eCollection 2018 Mar-Apr.

17.
18.

Genetic diversity assessed by genotyping by sequencing (GBS) and for phenological traits in blueberry cultivars.

Campa A, Ferreira JJ.

PLoS One. 2018 Oct 23;13(10):e0206361. doi: 10.1371/journal.pone.0206361. eCollection 2018.

19.

Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.

Fabbri M, Zibetti M, Beccaria L, Merola A, Romagnolo A, Montanaro E, Ferreira JJ, Palermo S, Lopiano L.

Eur J Neurol. 2019 Mar;26(3):490-496. doi: 10.1111/ene.13844. Epub 2018 Nov 18.

PMID:
30347489
20.

Oxytocin can regulate myometrial smooth muscle excitability by inhibiting the Na+ -activated K+ channel, Slo2.1.

Ferreira JJ, Butler A, Stewart R, Gonzalez-Cota AL, Lybaert P, Amazu C, Reinl EL, Wakle-Prabagaran M, Salkoff L, England SK, Santi CM.

J Physiol. 2019 Jan;597(1):137-149. doi: 10.1113/JP276806. Epub 2018 Nov 22.

PMID:
30334255
21.

Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.

Fabbri M, Rosa MM, Ferreira JJ.

Drugs Aging. 2018 Dec;35(12):1041-1054. doi: 10.1007/s40266-018-0599-2. Review.

PMID:
30318555
22.

Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions.

Rato ML, Duarte GS, Mestre T, de Carvalho M, Ferreira JJ.

Lancet Neurol. 2018 Oct;17(10):842. doi: 10.1016/S1474-4422(18)30310-7. Epub 2018 Sep 18. No abstract available.

PMID:
30264722
23.

Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.

Fabbri M, Ferreira JJ, Lees A, Stocchi F, Poewe W, Tolosa E, Rascol O.

Mov Disord. 2018 Oct;33(10):1528-1539. doi: 10.1002/mds.27475. Epub 2018 Sep 27. Review.

PMID:
30264443
24.

The placebo response in Parkinson's disease and other movement disorders.

Mestre TA, Ferreira JJ.

Mov Disord. 2018 Aug;33(8):1193-1194. doi: 10.1002/mds.27476. No abstract available.

PMID:
30230628
25.

Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?

Ferreira JJ, Trenkwalder C, Mestre TA.

Mov Disord. 2018 Aug;33(8):1228-1235. doi: 10.1002/mds.113. Review.

PMID:
30230626
26.

Risk of drowning in people with Parkinson's disease.

Neves MA, Bouça-Machado R, Guerreiro D, Caniça V, Ferreira JJ.

Mov Disord. 2018 Sep;33(9):1507-1508. doi: 10.1002/mds.27473. Epub 2018 Sep 12. No abstract available.

PMID:
30207614
27.

Validation of a Lower Back "Wearable"-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment.

Pham MH, Warmerdam E, Elshehabi M, Schlenstedt C, Bergeest LM, Heller M, Haertner L, Ferreira JJ, Berg D, Schmidt G, Hansen C, Maetzler W.

Front Neurol. 2018 Aug 10;9:652. doi: 10.3389/fneur.2018.00652. eCollection 2018.

28.

The European Physiotherapy Guideline for Parkinson's Disease: Implications for Neurologists.

Domingos J, Keus SHJ, Dean J, de Vries NM, Ferreira JJ, Bloem BR.

J Parkinsons Dis. 2018;8(4):499-502. doi: 10.3233/JPD-181383.

PMID:
30149464
29.

Immune Response Related With Skin Thermal Pattern in Judokas: A New Application for Infrared Thermography?

Brito CJ, Moreira DG, Ferreira JJ, Díaz-de-Durana AL, Miarka B, Marins JCB, Sillero-Quintana M.

J Strength Cond Res. 2018 Jun 25. doi: 10.1519/JSC.0000000000002672. [Epub ahead of print]

PMID:
29952866
30.

Physician perception versus true efficacy of tetrabenazine for Huntington's disease.

Rodrigues FB, Ferreira JJ, Wild EJ.

Curr Med Res Opin. 2018 Sep;34(9):1537-1538. doi: 10.1080/03007995.2018.1490703. Epub 2018 Jul 19. No abstract available.

PMID:
29920125
31.

Zebrafish as an Animal Model for Drug Discovery in Parkinson's Disease and Other Movement Disorders: A Systematic Review.

Vaz RL, Outeiro TF, Ferreira JJ.

Front Neurol. 2018 Jun 1;9:347. doi: 10.3389/fneur.2018.00347. eCollection 2018.

32.

Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?

Duarte GS, Rodrigues FB, Ferreira JJ, Costa J.

Parkinsonism Relat Disord. 2018 Nov;56:16-19. doi: 10.1016/j.parkreldis.2018.06.017. Epub 2018 Jun 15.

PMID:
29910156
33.

Non-vitamin K antagonist oral anticoagulants and infective endocarditis.

Caldeira D, Ferreira JJ, Pinto FJ, Costa J.

Heart. 2018 Jul;104(13):1135-1136. doi: 10.1136/heartjnl-2018-313168. No abstract available.

PMID:
29895673
34.

LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study.

Quadri M, Mandemakers W, Grochowska MM, Masius R, Geut H, Fabrizio E, Breedveld GJ, Kuipers D, Minneboo M, Vergouw LJM, Carreras Mascaro A, Yonova-Doing E, Simons E, Zhao T, Di Fonzo AB, Chang HC, Parchi P, Melis M, Correia Guedes L, Criscuolo C, Thomas A, Brouwer RWW, Heijsman D, Ingrassia AMT, Calandra Buonaura G, Rood JP, Capellari S, Rozemuller AJ, Sarchioto M, Fen Chien H, Vanacore N, Olgiati S, Wu-Chou YH, Yeh TH, Boon AJW, Hoogers SE, Ghazvini M, IJpma AS, van IJcken WFJ, Onofrj M, Barone P, Nicholl DJ, Puschmann A, De Mari M, Kievit AJ, Barbosa E, De Michele G, Majoor-Krakauer D, van Swieten JC, de Jong FJ, Ferreira JJ, Cossu G, Lu CS, Meco G, Cortelli P, van de Berg WDJ, Bonifati V; International Parkinsonism Genetics Network.

Lancet Neurol. 2018 Jul;17(7):597-608. doi: 10.1016/S1474-4422(18)30179-0. Epub 2018 Jun 7.

PMID:
29887161
35.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, Soares-da-Silva P.

Neurology. 2018 May 22;90(21):e1849-e1857. doi: 10.1212/WNL.0000000000005557. Epub 2018 Apr 25.

PMID:
29695590
36.

What is Functional Mobility Applied to Parkinson's Disease?

Bouça-Machado R, Maetzler W, Ferreira JJ.

J Parkinsons Dis. 2018;8(1):121-130. doi: 10.3233/JPD-171233.

37.

Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study.

Caldeira D, Rodrigues R, Abreu D, Anes AM, Rosa MM, Ferreira JJ.

Expert Opin Drug Saf. 2018 Apr;17(4):339-345. doi: 10.1080/14740338.2018.1439474. Epub 2018 Feb 20.

PMID:
29463153
38.

Why Palliative Care Applies to Parkinson's Disease.

Bouça-Machado R, Lennaerts-Kats H, Bloem B, Ferreira JJ.

Mov Disord. 2018 May;33(5):750-753. doi: 10.1002/mds.27309. Epub 2018 Feb 13. No abstract available.

PMID:
29436747
39.

A rare cause of orofacial dyskinesias.

Miranda B, Mestre TA, Rodrigues D, Coelho M, Ferreira JJ.

Parkinsonism Relat Disord. 2018 May;50:122-123. doi: 10.1016/j.parkreldis.2018.02.002. Epub 2018 Feb 7. No abstract available.

PMID:
29429646
40.

Feasibility of using risk prompts to prevent falls, dehydration and pulmonary aspiration in nursing homes: a clinical study protocol.

Duarte M, Bouça-Machado R, Domingos J, Godinho C, Ferreira JJ; CNS risk prompt display study group.

Pilot Feasibility Stud. 2018 Jan 25;4:39. doi: 10.1186/s40814-018-0236-1. eCollection 2018.

41.

The launch of opicapone for Parkinson's disease: negatives versus positives.

Castro Caldas A, Teodoro T, Ferreira JJ.

Expert Opin Drug Saf. 2018 Mar;17(3):331-337. doi: 10.1080/14740338.2018.1433659. Review.

PMID:
29415596
42.

Influenza vaccination and prevention of cardiovascular disease mortality.

Caldeira D, Ferreira JJ, Costa J.

Lancet. 2018 Feb 3;391(10119):426-427. doi: 10.1016/S0140-6736(18)30143-0. No abstract available.

PMID:
29407029
43.

Psychosocial impact of Parkinson's disease-associated dysarthria: Cross-cultural adaptation and validation of the Dysarthria Impact Profile into European Portuguese.

Cardoso R, Guimarães I, Santos H, Loureiro R, Domingos J, Abreu D, Gonçalves N, Pinto S, Ferreira JJ.

Geriatr Gerontol Int. 2018 May;18(5):767-774. doi: 10.1111/ggi.13255. Epub 2018 Jan 26.

PMID:
29372587
44.

Serological and molecular inquiry of Chagas disease in an Afro-descendant settlement in Mato Grosso do Sul State, Brazil.

Martins MFDS, Pereira MB, Ferreira JJG, França AO, Cominetti MC, Ferreira EC, Dorval MEMC, Rossi CL, Mazon SB, de Almeida EA, Costa SCB, Marcon GEB.

PLoS One. 2018 Jan 9;13(1):e0189448. doi: 10.1371/journal.pone.0189448. eCollection 2018.

45.

A Perspective on Wearable Sensor Measurements and Data Science for Parkinson's Disease.

Matias R, Paixão V, Bouça R, Ferreira JJ.

Front Neurol. 2017 Dec 12;8:677. doi: 10.3389/fneur.2017.00677. eCollection 2017.

46.

Correction: Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles.

Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Gonçalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltényi G, Borovecki F, Soreq H, Ferreira JJ, Outeiro TF.

PLoS One. 2017 Dec 28;12(12):e0190552. doi: 10.1371/journal.pone.0190552. eCollection 2017.

47.

Comments on: 'Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial'.

Simões RM, Castro Caldas A, Ferreira JJ.

Eur J Neurol. 2018 Jan;25(1):e4. doi: 10.1111/ene.13475. No abstract available.

PMID:
29271586
48.

Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease".

Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ.

J Clin Mov Disord. 2017 Nov 22;4:19. doi: 10.1186/s40734-017-0067-x. eCollection 2017.

49.

Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease.

Vicente Miranda H, Cássio R, Correia-Guedes L, Gomes MA, Chegão A, Miranda E, Soares T, Coelho M, Rosa MM, Ferreira JJ, Outeiro TF.

Sci Rep. 2017 Oct 20;7(1):13713. doi: 10.1038/s41598-017-14175-5.

50.

Quality and reporting of guidelines on the diagnosis and management of dystonia.

Tamás G, Abrantes C, Valadas A, Radics P, Albanese A, Tijssen MAJ, Ferreira JJ.

Eur J Neurol. 2018 Feb;25(2):275-283. doi: 10.1111/ene.13488. Epub 2017 Dec 22.

PMID:
29053896

Supplemental Content

Loading ...
Support Center